ArticleJournal of materials science. Materials in medicine2026
Comparative hemocompatibility assessment of fibrin/heparin-coated and PMEA-coated flow diverters.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flow diverters play an important role in the endovascular treatment of intracranial aneurysms; however, their use can be associated with thromboembolic complications. Thus, in recent years, flow diverters with surface coatings have been developed to prevent thrombus-related complications. In this study, the hemocompatibility of the flow diverters FRED X with poly(2-methoxyethyl acrylate) (PMEA) coating and the DERIVO 2heal with fibrin/heparin coating, as well as the uncoated DERIVO 2 flow diverter, was evaluated using an in vitro blood circulation model. Using enzyme-linked immunosorbent assay (ELISA), biomarkers of thrombocytes (β-thromboglobulin (β-TG)), coagulation (thrombin-antithrombin complex (TAT)), complement system (SC5b-9), and inflammation (PMN elastase) activation were analyzed. Further analyses comprised thrombogenicity assessment by scanning electron microscopy and measurement of blood cell counts and hemolysis. The uncoated DERIVO 2 flow diverter exhibited increased coagulation and platelet activation, accompanied by enhanced adhesion of platelets to the blood-contacting surfaces. In contrast, both the FRED X and the DERIVO 2-heal flow diverter could effectively reduce the coagulation (TAT) and platelet activation (β-TG) and prevent the adhesion of platelets. Notably, DERIVO 2heal flow diverter induced significantly lower activation of the complement system (SC5b-9) and reduced inflammatory response (PMN elastase) compared to FRED X flow diverter. These findings indicate the improved hemocompatibility of the fibrin/heparin-coated DERIVO 2heal flow diverter and its potential to reduce thromboinflammatory complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.